These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 7139646)

  • 1. Phase I study of SOAz.
    Nasca S; Jezekova D; Coninx P; Garbe E; Carpentier Y; Cattan A
    Cancer Treat Rep; 1982 Dec; 66(12):2039-42. PubMed ID: 7139646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I clinical and pharmacokinetic trial of hepsulfam.
    Ravdin PM; Havlin KA; Marshall MV; Brown TD; Koeller JM; Kuhn JG; Rodriguez G; Von Hoff DD
    Cancer Res; 1991 Dec; 51(23 Pt 1):6268-72. PubMed ID: 1933887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and clinical pharmacologic studies of aziridinylbenzoquinone.
    Griffin JP; Newman RA; McCormack JJ; Krakoff IH
    Cancer Treat Rep; 1982 Jun; 66(6):1321-5. PubMed ID: 7083235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I clinical trial of (NPAz2)2NSOAz: 'SOAz'.
    Rodenhuis S; Mulder NH; Sleijfer DT; Koops HS; van de Grampel JC
    Cancer Chemother Pharmacol; 1983; 10(3):178-81. PubMed ID: 6861263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I; Bench K; Beijnen JH; Bruntsch U; Cavalli F; de Jong J; Groot Y; van Tellingen O; Wanders J; Sessa C
    Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
    Nicaise C; Rozencweig M; Crespeigne N; Dodion P; Gerard B; Lambert M; Decoster G; Kenis Y
    Cancer Treat Rep; 1986 May; 70(5):599-603. PubMed ID: 3708609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of arabinofuranosyl-5-azacytosine (fazarabine, NSC 281272).
    Surbone A; Ford H; Kelley JA; Ben-Baruch N; Thomas RV; Fine R; Cowan KH
    Cancer Res; 1990 Feb; 50(4):1220-5. PubMed ID: 1688736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of aziridinylbenzoquinone (AZQ) in advanced large bowel carcinoma.
    Rubin J; van Hazel GA; Schutt AJ; Moertel CG; O'Connell MJ
    Am J Clin Oncol; 1982 Oct; 5(5):539-40. PubMed ID: 7180832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.
    Woodcock TM; Schneider RJ; Young CW
    Cancer Treat Rep; 1980 Jan; 64(1):53-5. PubMed ID: 6892893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial: pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study.
    Roh JK; Rha SY; Lee CI; Lee KH; Lee JJ; Shim HJ; Lee SD; Kim WB; Yang J; Kim SH; Lee MG
    Int J Clin Pharmacol Ther; 1998 Jun; 36(6):312-9. PubMed ID: 9660038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II clinical evaluation of AZQ in colorectal cancer.
    Bedikian AY; Stroehlein JR; Karlin DA; Korinek J; Bodey GP
    Am J Clin Oncol; 1982 Oct; 5(5):535-7. PubMed ID: 7180831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical study of dihydroxyanthracenedione administered on a 5-day iv schedule.
    Valdivieso M; Bedikian AY; Burgess MA; Savaraj N; Jeffers WB; Bodey GP
    Cancer Treat Rep; 1981; 65(9-10):841-4. PubMed ID: 7273017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule.
    Von Hoff DD; Howser K; Gormley P; Bender RA; Glaubiger D; Levine AS; Young RC
    Cancer Treat Rep; 1978 Oct; 62(10):1421-6. PubMed ID: 361222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of diaziquone.
    Frytak S; Eagan RT; Ames MM; Creagan ET; Nichols WC
    Cancer Treat Rep; 1984; 68(7-8):975-8. PubMed ID: 6744349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of dihydroxyanthracenedione.
    Van Echo DA; Whitacre MY; Aisner J; Wiernik PH
    Cancer Treat Rep; 1981; 65(9-10):831-4. PubMed ID: 7273015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule.
    Khayat D; Lokiec F; Bizzari JP; Weil M; Meeus L; Sellami M; Rouesse J; Banzet P; Jacquillat C
    Cancer Res; 1987 Dec; 47(24 Pt 1):6782-5. PubMed ID: 3677107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione).
    Wynert WR; Harvey HA; Lipton A; Schweitzer J; White DS
    Cancer Treat Rep; 1982 Jun; 66(6):1303-6. PubMed ID: 7083234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study.
    Hochster H; Liebes L; Speyer J; Sorich J; Taubes B; Oratz R; Wernz J; Chachoua A; Blum RH; Zeleniuch-Jacquotte A
    Clin Cancer Res; 1997 Aug; 3(8):1245-52. PubMed ID: 9815806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I trial of mitoxantrone by 24-hour continuous infusion.
    Anderson KC; Garnick MB; Meshad MW; Cohen GI; Pegg WJ; Frei E; Israel M; Modest E; Canellos GP
    Cancer Treat Rep; 1983 May; 67(5):435-8. PubMed ID: 6850662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.